Journal
TRENDS IN IMMUNOLOGY
Volume 34, Issue 12, Pages 592-601Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2013.07.002
Keywords
-
Categories
Funding
- CLL Global Research Foundation
- Cancer Prevention and Research Institute of Texas (CPRIT)
- Leukemia & Lymphoma Society Scholar Award in Clinical Research
- NIH/NCI [CA081554]
Ask authors/readers for more resources
B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR-dependent survival and growth of the malignant B cells. In CLL and lymphoma subtypes, ligand-independent ('tonic') and ligand-dependent BCR signaling have been characterized, which can involve mutations of BCR pathway components or be triggered by (auto)antigens present in the tissue microenvironment. In CLL, based on high response rates and durable remissions in early-stage clinical trials, there is rapid clinical development of inhibitors targeting BCR-associated kinases [Bruton's tyrosine kinase (BTK), phosphoinositide 3-kinase (PI3K)delta], which will change treatment paradigms in CLL and other B cell malignancies. Here, we discuss the evolution of this field, from BCR-related prognostic markers, to mechanisms of BCR activation, and targeting of BCR-associated kinases, the emerging Achilles' heel in CLL pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available